← 產業報告目錄
Omics-Based Clinical Trials Market Size, Share & Trends Analysis Report By Phase Type (Phase I, Phase II, Phase III, and Phase IV), By Study Design Type (Interventional Studies, Observational Studies, and Expanded Access Studies), By Indication Type (Oncology, Cardiology, Respiratory Diseases, Skin Diseases, CNS Diseases, Immunology, Genetic Diseases, and Others), By Region, And By Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-04頁數 180報告編號 INSIGHTACE-ae6460147f
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
With a 2023 valuation of USD 29.51 billion, the global Omics-Based Clinical Trials Market is poised to expand to USD 54.42 billion by 2031, demonstrating a CAGR of 8.13% during the 2023–2031 forecast window.
Omics-Based Clinical Trials covers reshaping how healthcare entities approach this space.
Growth is bolstered by a convergence of factors: rising awareness among end users, continuous product innovation, and the rising emphasis on efficiency and sustainability within the healthcare sector.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region poised to deliver the strongest growth trajectory through the forecast period, bolstered by demographic shifts and policy support.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Omics-Based Clinical Trials Market Snapshot
Chapter 4. Global Omics-Based Clinical Trials Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Phase Type Estimates & Trend Analysis
5.1. by Phase Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Phase Type:
5.2.1. Phase I
5.2.2. Phase II
5.2.3. Phase III
5.2.4. Phase IV
Chapter 6. Market Segmentation 2: by Study Design Type Estimates & Trend Analysis
6.1. by Study Design Type & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Study Design Type:
6.2.1. interventional studies
6.2.2. observational studies
6.2.3. expanded access studies
Chapter 7. Market Segmentation 3: by Indication Type Estimates & Trend Analysis
7.1. by Indication Type & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Indication Type:
7.2.1. oncology
7.2.2. cardiology
7.2.3. respiratory diseases
7.2.4. skin diseases
7.2.5. CNS diseases
7.2.6. immunology
7.2.7. genetic diseases
7.2.8. others
Chapter 8. Omics-Based Clinical Trials Market Segmentation 6: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Omics-Based Clinical Trial Market Revenue (US$ Million) Estimates and Forecasts by Phase Type, 2019-2031
8.1.2. North America Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Study Design Type, 2019-2031
8.1.3. North America Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Indication Type, 2019-2031
North America Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.2. Europe
8.2.1. Europe Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Phase Type, 2019-2031
8.2.2. Europe Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Study Design Type, 2019-2031
8.2.3. Europe Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Indication Type, 2019-2031
8.2.4. Europe Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Phase Type, 2019-2031
8.3.2. Asia Pacific Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Study Design Type, 2019-2031
8.3.3. Asia-Pacific Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Indication Type, 2019-2031
8.3.4. Asia Pacific Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.4. Latin America
8.4.1. Latin America Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Phase Type, 2019-2031
8.4.2. Latin America Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Study Design Type, 2019-2031
8.4.3. Latin America Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Indication Type, 2019-2031
8.4.4. Latin America Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Phase Type, 2019-2031
8.5.2. Middle East & Africa Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Study Design Type, 2019-2031
8.5.3. Middle East & Africa Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Indication Type, 2019-2031
8.5.4. Middle East & Africa Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Pfizer Inc.
9.2.2. Covance Inc.
9.2.3. Parexel International Corporation
9.2.4. Charles River Laboratory
9.2.5. Icon Plc
9.2.6. Eli Lilly and Company
9.2.7. Rebus Bio
9.2.8. Novo Nordisk
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們